Evidence map›Paper›PMID 33204120›Full record

ArticleInfection and drug resistance2020

Prevalence and Determinants of Multidrug-Resistant Tuberculosis in Makkah, Saudi Arabia.

Mohammad Fouad Mohammad Khatib Sambas, Unaib Rabbani, Manal Mansour Mezal Al-Gethamy, Saud Hasan Surbaya, Faisal Fuwaran Irmat Alharbi, Riyadh Ghazi Abdulrahman Ahmad, Hamzah Khalid Hamzah Qul, Safa Mohammed Saeed Nassar, Abdulaziz Khalid Mohammed Ali Maddah, Basel Ali Kabah Darweesh

Open access · goldAbstract read
In one paragraph

Article in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 4 pooled it
0.3field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Transmission of Antimicrobial Resistant Bacteria at the Hajj: A Scoping Review.International journal of environmental research and public health · 2022
    Article
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Mohammad Fouad Mohammad Khatib SambasDepartment of Infectious Diseases, King Abdulaziz Hospital, Makkah, Saudi Arabia.
Unaib RabbaniFamily Medicine Academy, Qassim Health Cluster, Buraidah, Saudi Arabia.ORCID 0000-0002-0702-780X
Manal Mansour Mezal Al-GethamyDepartment of Infection Prevention & Control, Alnoor Specialist Hospital, Makkah, Saudi Arabia.
Saud Hasan SurbayaTraining, Education and Research Department, Makkah Public Health, Ministry of Health, Makkah, Saudi Arabia.ORCID 0000-0003-0776-1788
Faisal Fuwaran Irmat AlharbiDepartment of Infection Control, King Abdulaziz Hospital, Makkah, Saudi Arabia.
Riyadh Ghazi Abdulrahman AhmadDepartment of Internal Medicine, Hera General Hospital, Makkah, Saudi Arabia.
Hamzah Khalid Hamzah QulEndocrinology Unit, Department of Internal Medicine, King Abdulaziz Hospital, Makkah, Saudi Arabia.
Safa Mohammed Saeed NassarDepartment of Internal Medicine, Alnoor Specialist Hospital, Makkah, Saudi Arabia.ORCID 0000-0003-0690-8223
Abdulaziz Khalid Mohammed Ali MaddahDepartment of Internal Medicine, Alnoor Specialist Hospital, Makkah, Saudi Arabia.
Basel Ali Kabah DarweeshDepartment of Internal Medicine, Alnoor Specialist Hospital, Makkah, Saudi Arabia.
Saad Specialist Hospital · SAKing Abdulaziz Hospital · SAHera General Hospital · SAMinistry of Health · SAQassim University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesTuberculosis (TB) is a global public health issue. The emergence of multidrug-resistant (MDR) TB has further complicated the situation in the form of poor treatment outcomes and costs to individuals and health-care systems. We therefore aimed to measure the prevalence and associated risk factors of MDR TB among TB patients in Makkah city. PATIENTS AND

methodsThis was a cross-sectional study conducted at Al-Noor Specialist Hospital, a public-sector hospital in Makkah. We included records of 158 confirmed TB patients from the list of all patients admitted in the hospital from January 2009 to January 2019 by systematic random sampling. Data were collected on socio-demographics, clinical profile and drug resistance patterns. Analysis was done in SPSS version 21.0.

resultsThe mean age of the participants was 43.4 ± 18.7 years, and two-thirds (66.5%) were male. About 40% of the patients had chronic disease while lung disease other than TB was present in 5% patients. About 13% of cases were extrapulmonary infections. Prevalence of drug resistance was found to be 17.1% among TB patients. Among the resistant cases, streptomycin (25.9%) and isoniazid (11.1%) were the drugs most commonly affected by resistance. Prevalence of MDR TB was 5% among TB patients. Age, smoking, lung disease and previous TB were significant factors associated with MDR TB.

conclusionPrevalence of MDR TB, although comparable to current national estimates, is higher compared to previous reports. There is a need to reduce this burden through strengthening TB control programs to prevent further emergence of a public health threat of MDR TB. History of previous TB was the strongest risk factor in this study. This calls physicians, program managers and policy makers to focus on counselling and support of TB patients for compliance with the regimen to complete treatment without interruption.

Indexed as

MDR TBprevalencerisk factorsSaudi Arabia

Identifiers

PMID33204120
PMCPMC7667158
OpenAlexW3105265884

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.